9 Meters Biopharma, Inc. (NMTRQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
9 Meters Biopharma, Inc. (NMTRQ) with AI Score 48/100 (Weak). 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare digestive diseases and gastrointestinal conditions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 20269 Meters Biopharma, Inc. (NMTRQ) Healthcare & Pipeline Overview
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on rare digestive diseases, including short bowel syndrome, and gastrointestinal conditions. Its lead product, Vurolenatide, is in Phase 3 trials. The company filed for Chapter 7 liquidation in 2023, impacting its future operations and potential for drug development within the competitive biotechnology sector.
Investment Thesis
The investment thesis for 9 Meters Biopharma, Inc. is significantly impacted by its Chapter 7 liquidation filing in July 2023. With a market capitalization of $0.00B and a negative ROE of -375.6%, the company's financial viability is uncertain. The high beta of 10.00 indicates extreme volatility. While Vurolenatide was in Phase 3 trials, the bankruptcy proceedings cast doubt on its future development and potential revenue generation. Investors should be aware of the high risks associated with companies undergoing liquidation, including the potential loss of investment.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates the company's distressed financial state.
- ROE of -375.6% reflects significant losses and financial instability.
- Free Cash Flow of $-0.00B highlights the company's inability to generate positive cash flow.
- Beta of 10.00 indicates extremely high volatility compared to the market average.
- Chapter 7 bankruptcy filing on July 17, 2023, signals the company's intent to liquidate its assets.
Competitors & Peers
Strengths
- Proprietary drug candidates in clinical development.
- Focus on rare and unmet medical needs.
- Licensing agreements with other companies.
- Experienced management team in drug development.
Weaknesses
- Chapter 7 bankruptcy filing.
- Limited financial resources.
- High dependence on clinical trial outcomes.
- Negative ROE and Free Cash Flow.
Catalysts
- Ongoing: Potential for asset sales during liquidation proceedings.
- Ongoing: Legal proceedings related to bankruptcy.
- Ongoing: Potential for restructuring or acquisition of assets.
Risks
- Ongoing: Chapter 7 bankruptcy leading to complete loss of investment.
- Potential: Delisting from the OTC market.
- Potential: Legal claims from creditors.
- Potential: Loss of intellectual property rights.
- Potential: Negative impact on reputation and future business prospects.
Growth Opportunities
- Advancement of Vurolenatide: Vurolenatide, a long-acting injectable glucagon-like-peptide-1 (GLP-1), was in Phase 3 clinical trials for treating short bowel syndrome (SBS). Successful completion of these trials and subsequent regulatory approval could have addressed a significant unmet need in the SBS market, estimated to reach $2.3 billion by 2028. However, the company's bankruptcy filing jeopardizes this potential growth driver.
- Development of NM-136: NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders, represented a potential expansion into a large and growing market. The global obesity market is projected to reach $40 billion by 2030, driven by increasing prevalence of obesity and related comorbidities. However, the bankruptcy filing casts doubt on the continued development of this asset.
- Expansion of NM-102: NM-102, a small molecule peptide designed to prevent antigens from trafficking into systemic circulation, could have addressed various autoimmune and inflammatory conditions. The market for autoimmune disease treatments is substantial, estimated at $60 billion globally. Further development of NM-102 could have opened new avenues for growth, but the bankruptcy filing impacts its future.
- Partnered Product Larazotide: Larazotide, an 8-amino acid peptide in Phase 2 clinical trials for multi-system inflammatory syndrome, represented a partnered opportunity. Positive trial results and subsequent commercialization could have generated revenue through royalties or milestone payments. However, the bankruptcy filing introduces uncertainty regarding the future of this partnership and the development of Larazotide.
- Licensing Agreements: 9 Meters Biopharma had licensing agreements with companies like Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. These agreements could have provided access to novel technologies and therapeutic candidates, potentially fueling future growth. However, the bankruptcy filing may impact the validity and continuation of these agreements.
Opportunities
- Potential for successful clinical trial results.
- Partnerships for further drug development.
- Market growth in rare digestive diseases.
- Advancements in biotechnology and drug delivery.
Threats
- Regulatory hurdles and approval delays.
- Competition from other pharmaceutical companies.
- Clinical trial failures.
- Economic downturn impacting healthcare spending.
Competitive Advantages
- Proprietary drug candidates targeting specific unmet needs.
- Intellectual property protection through patents and exclusivity.
- Clinical trial data supporting efficacy and safety.
- Licensing agreements providing access to novel technologies.
About NMTRQ
9 Meters Biopharma, Inc. was a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for rare and unmet needs in digestive diseases. Founded with the mission to improve the lives of patients with gastrointestinal disorders, the company focused on developing treatments for conditions like short bowel syndrome (SBS) and other debilitating digestive ailments. Its lead product candidate, Vurolenatide, a long-acting injectable glucagon-like-peptide-1 (GLP-1), reached Phase 3 clinical trials for the treatment of SBS, representing a significant milestone in its development pipeline. In addition to Vurolenatide, 9 Meters Biopharma was also developing NM-136, a humanized monoclonal antibody for obesity and related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. The company also had a partnered product, Larazotide, an 8-amino acid peptide in Phase 2 trials for multi-system inflammatory syndrome. 9 Meters Biopharma operated through licensing agreements with companies like Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. Headquartered in Raleigh, North Carolina, the company's operations came to a halt when it filed a voluntary petition for liquidation under Chapter 7 bankruptcy on July 17, 2023.
What They Do
- Develops treatments for rare digestive diseases.
- Focuses on gastrointestinal conditions with unmet needs.
- Develops therapies for debilitating disorders.
- Lead product candidate was Vurolenatide for short bowel syndrome.
- Developing NM-136 for obesity and obesity-related disorders.
- Developing NM-102 to prevent antigens from trafficking into systemic circulation.
- Developing NM-003 for prevention of acute graft versus host disease.
- Partnered product Larazotide for multi-system inflammatory syndrome.
Business Model
- Develops pharmaceutical products through internal research and development.
- Out-licenses or partners with other companies for development and commercialization.
- Generates revenue through potential future sales of approved drugs.
- Relies on licensing agreements for technology and product development.
Industry Context
9 Meters Biopharma operated within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant risks of clinical trial failures. Companies in this sector often focus on niche markets and rare diseases to gain regulatory advantages and market exclusivity. However, the company's bankruptcy filing reflects the challenges faced by smaller biotech firms in securing funding and navigating the complexities of drug development. Competitors like ADYX and BIMI operate in similar therapeutic areas, highlighting the competitive pressure in the market.
Key Customers
- Patients with rare digestive diseases.
- Healthcare providers treating gastrointestinal conditions.
- Hospitals and clinics specializing in digestive disorders.
- Pharmaceutical companies through licensing and partnership agreements.
Financials
Chart & Info
9 Meters Biopharma, Inc. (NMTRQ) stock price: Price data unavailable
Latest News
No recent news available for NMTRQ.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NMTRQ.
Price Targets
Wall Street price target analysis for NMTRQ.
MoonshotScore
What does this score mean?
The MoonshotScore rates NMTRQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Peter H. R. Green
CEO
Peter H. R. Green served as the CEO of 9 Meters Biopharma, Inc. His background includes experience in managing pharmaceutical companies and overseeing the development of clinical-stage drug candidates. He has a track record in the biotechnology industry, with expertise in corporate strategy, business development, and clinical operations. His leadership was focused on advancing the company's pipeline of therapies for rare digestive diseases.
Track Record: Under Peter H. R. Green's leadership, 9 Meters Biopharma focused on advancing its lead product candidate, Vurolenatide, through Phase 3 clinical trials. He oversaw the development of other drug candidates, including NM-136, NM-102, and NM-003. However, his tenure concluded with the company filing for Chapter 7 bankruptcy, impacting the future of these programs.
NMTRQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that 9 Meters Biopharma, Inc. did not meet the requirements for the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, be undergoing bankruptcy, or have regulatory issues. Investing in OTC Other stocks carries significantly higher risks compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of stringent listing standards and regulatory oversight. The OTC Other tier often includes shell companies, defunct companies, and companies with questionable business practices.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for fraud or manipulation.
- Bankruptcy proceedings.
- Lack of regulatory oversight.
- Verify the company's legal status and registration.
- Review any available financial statements.
- Assess the company's assets and liabilities.
- Investigate the background of the management team.
- Determine the reasons for trading on the OTC Other tier.
- Understand the risks associated with investing in bankrupt companies.
- Consult with a financial advisor.
- Previous clinical-stage development of drug candidates.
- Prior licensing agreements with other companies.
- Historical focus on addressing unmet medical needs.
- Listing on OTC market (however, this is a weak signal due to the OTC Other tier)
NMTRQ Healthcare Stock FAQ
What does 9 Meters Biopharma, Inc. do?
9 Meters Biopharma, Inc. was a clinical-stage biopharmaceutical company focused on developing treatments for rare digestive diseases and gastrointestinal conditions with unmet needs. Its lead product candidate was Vurolenatide, a long-acting injectable glucagon-like-peptide-1 (GLP-1) in Phase 3 clinical trials for short bowel syndrome (SBS). The company also developed other drug candidates for obesity, inflammatory conditions, and graft versus host disease. However, the company filed for Chapter 7 bankruptcy in July 2023, impacting its operations and future prospects.
What do analysts say about NMTRQ stock?
Given 9 Meters Biopharma, Inc.'s Chapter 7 bankruptcy filing, formal analyst coverage is likely limited or non-existent. The company's financial instability and liquidation proceedings make it a highly speculative investment. Key valuation metrics are likely negative or irrelevant. Investors should exercise extreme caution and conduct thorough due diligence before considering any investment in NMTRQ. The bankruptcy filing significantly alters the investment landscape for the company.
What are the main risks for NMTRQ?
The primary risk for 9 Meters Biopharma, Inc. is the ongoing Chapter 7 bankruptcy proceedings, which could result in a complete loss of investment for shareholders. Additional risks include delisting from the OTC market, potential legal claims from creditors, loss of intellectual property rights, and negative impact on the company's reputation. The company's financial instability and lack of revenue generation further exacerbate these risks. Investors should carefully consider these factors before investing.
What are the key factors to evaluate for NMTRQ?
9 Meters Biopharma, Inc. (NMTRQ) currently holds an AI score of 48/100, indicating low score. Key strength: Proprietary drug candidates in clinical development.. Primary risk to monitor: Ongoing: Chapter 7 bankruptcy leading to complete loss of investment.. This is not financial advice.
How frequently does NMTRQ data refresh on this page?
NMTRQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NMTRQ's recent stock price performance?
Recent price movement in 9 Meters Biopharma, Inc. (NMTRQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary drug candidates in clinical development.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NMTRQ overvalued or undervalued right now?
Determining whether 9 Meters Biopharma, Inc. (NMTRQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NMTRQ?
Before investing in 9 Meters Biopharma, Inc. (NMTRQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The company's bankruptcy proceedings introduce significant uncertainty.